Get the Stockscreener App
44.90
2.10%
0.925
Pre-market:
45.10
0.205
+0.46%
Dianthus Therapeutics Inc stock is traded at $44.90, with a volume of 405.70K.
It is up +2.10% in the last 24 hours and up +35.23% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$43.97
Open:
$43.72
24h Volume:
405.70K
Relative Volume:
0.50
Market Cap:
$1.92B
Revenue:
$4.85M
Net Income/Loss:
$-114.75M
P/E Ratio:
-13.81
EPS:
-3.25
Net Cash Flow:
$-100.36M
1W Performance:
+1.96%
1M Performance:
+35.23%
6M Performance:
+149.97%
1Y Performance:
+81.91%
1-Day Range:
$43.28
$45.45
1-Week Range:
$42.00
$45.45
52-Week Range:
$13.37
$45.45
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
44.90 | 1.89B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics stock hits 52-week high at 45.0 USD - Investing.com
Can Dianthus Therapeutics Inc. (87E) stock deliver double digit returnsPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - Newser
Will Dianthus Therapeutics Inc. (87E) stock outperform value peersTrade Risk Assessment & Low Risk High Reward Ideas - Newser
Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC - MarketBeat
CapEx per share of Dianthus Therapeutics, Inc. – TRADEGATE:87E - TradingView
DNTH: Advancing two autoimmune therapies with strong clinical data and $525M cash runway - TradingView
Is Dianthus Therapeutics Inc. (87E) stock a contrarian opportunityQuarterly Market Summary & Consistent Growth Stock Picks - Newser
Can Dianthus Therapeutics Inc. (87E) stock sustain breakout momentumJuly 2025 Breakouts & AI Optimized Trade Strategies - Newser
Ensign Peak Advisors Inc Invests $2.50 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Stocks of Dianthus Therapeutics Inc (DNTH) are poised to climb above their peers - Setenews
Fed fueled market rally dnth breakout setup and ethereums critical test zone ahead | Fundamental analysis - RichTv
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighShould You Buy? - MarketBeat
Avidity Partners Management LP Reduces Stake in Dianthus Therape - GuruFocus
What analysts say about Dianthus Therapeutics Inc stockStock Buy Signals & Top Analyst Picks Available for Free - earlytimes.in
Dianthus Therapeutics stock hits 52-week high at 43.69 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2 - Stock Titan
The Insider Report: Prepare for the Next Dip Buying Opportunity - Benzinga
DNTH SEC FilingsDianthus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wedbush Maintains Dianthus Therapeutics (DNTH) Outperform Recommendation - MSN
How forex fluctuations impact Dianthus Therapeutics Inc. (87E) stockPortfolio Gains Summary & Safe Capital Growth Trade Ideas - newser.com
Why Dianthus Therapeutics Inc. stock remains resilient2025 Short Interest & Real-Time Volume Triggers - newser.com
How Dianthus Therapeutics Inc. (87E) stock performs in easing cyclesCEO Change & Daily Entry Point Alerts - newser.com
How Dianthus Therapeutics Inc. stock reacts to global recession fearsJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com
Views of Wall Street’s Leading Experts on Dianthus Therapeutics Inc - Setenews
Smart tools for monitoring Dianthus Therapeutics Inc.’s price action2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
What analysts say about Dianthus Therapeutics Inc 87E stock - earlytimes.in
How to escape a deep drawdown in Dianthus Therapeutics Inc.Earnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $3,221,132.67 in Stock - Defense World
Candriam S.C.A. Has $4.48 Million Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Dianthus Therapeutics Insider Sold Shares Worth $7,379,887, According to a Recent SEC Filing - MarketScreener
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month High – Here’s Why - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 109,031 Shares - MarketBeat
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 87,507 Shares of Stock - MarketBeat
What dividend safety score for Dianthus Therapeutics Inc. stock2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighWhat's Next? - MarketBeat
Will Dianthus Therapeutics Inc. (87E) stock hit Wall Street targetsWeekly Trend Summary & Real-Time Buy Zone Alerts - newser.com
Can Dianthus Therapeutics Inc. stock hit analyst price targetsEarnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results - Quiver Quantitative
Is Dianthus Therapeutics Inc. (87E) stock a fit for income portfoliosNew Guidance & Safe Entry Point Identification - newser.com
What recovery options are there for Dianthus Therapeutics Inc.July 2025 Drop Watch & Low Drawdown Trading Techniques - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 6.7%Here's What Happened - MarketBeat
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):